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Recurrent deletions and duplications at the 2q13 locus have been associated with developmental
delay (DD) and dysmorphisms. We aimed to undertake detailed clinical characterization of individ-
uals with 2q13 copy number variations (CNVs), with a focus on behavioral and psychiatric
phenotypes. Participants were recruited via the Unique chromosomal disorder support group, U.K.
National Health Service Regional Genetics Centres, and the DatabasE of genomiC varIation and
Phenotype in Humans using Ensembl Resources (DECIPHER) database. A review of published
2q13 patient case reports was undertaken to enable combined phenotypic analysis. We present a
new case series of 2q13 CNV carriers (21 deletion, 4 duplication) and the largest ever combined
analysis with data from published studies, making a total of 54 deletion and 23 duplication carriers.
DD/intellectual disabilities was identified in the majority of carriers (79% deletion, 70% duplica-
tion), although in the new cases 52% had an IQ in the borderline or normal range. Despite the
median age of the new cases being only 9 years, 64% had a clinical psychiatric diagnosis.
Combined analysis found attention deficit hyperactivity disorder (ADHD) to be the most frequent
diagnosis (48% deletion, 60% duplication), followed by autism spectrum disorders (33% deletion,
17% duplication). Aggressive (33%) and self-injurious behaviors (33%) were also identified in the
new cases. CNVs at 2q13 are typically associated with DD with mildly impaired intelligence, and a
high rate of childhood psychiatric diagnoses—particularly ADHD. We have further characterized
the clinical phenotype related to imbalances of the 2q13 region and identified it as a region of
interest for the neurobiological investigation of ADHD.
K E YWORD S
attention deficit hyperactivity disorder, autism spectrum disorders, copy number variants, develop-
mental delay, intellectual disabilities
1 | INTRODUCTION
Chromosomal microarray analysis technologies have led to the discov-
ery of chromosomal imbalances across the human genome. These
imbalances, or copy number variations (CNVs), comprise deletions or
duplications affecting single or multiple genes on sections of the chro-
mosome. CNVs occur as part of natural variation and can be benign in
nature. Typically, it is the rare CNVs, occurring in less than 1% of the
population, that are enriched in individuals with neurodevelopmental
and neuropsychiatric phenotypes (Iyer & Girirajan, 2015). Several chal-
lenges, however, remain in CNV interpretation. CNVs frequently dis-
play reduced penetrance, meaning not everyone with the CNV displays
the disease phenotype, and/or variable expressivity, whereby the
severity of the phenotype differs between CNV carriers (Rosenfeld,
Coe, Eichler, Cuckle, & Shaffer, 2013).
Certain regions of the genome are more liable to recurrent CNVs.
These regions are flanked by segmental duplications (SDs), also known
as low copy repeats, which are prone to mismatching of repetitive
DNA sequences mediated by non-allelic homologous recombination
(Malhotra & Sebat, 2012). Investigation of chromosomal rearrange-
ments in regions of SD, identified 2q13 CNVs in patients with develop-
mental disorders (Rudd et al., 2009). However, the pathogenicity of
these CNVs was initially described as of uncertain significance. This
was due to a 2q13 duplication also being found in a healthy control
(Rudd et al., 2009), and the findings from a previous study that the
same 2q13 deletion in two siblings with developmental problems had
been inherited from an unaffected parent (Bisgaard et al., 2007).
Analysis of larger samples revealed that 2q13 CNVs are associated
with an increased risk of developmental delay (DD) and intellectual dis-
abilities (IDs). Cooper et al. (2011) reported 12 deletions and 9 duplica-
tions in cases with developmental disorders (N515,767) and 1
deletion and 0 duplications in controls (N58,329). They found an
enrichment of the deletion (p5 .032) and duplication (p5 .022) in
cases, as compared to controls. The deletion was associated with cardi-
ovascular disorders, whereas the duplication was associated with cra-
niofacial features (Cooper et al., 2011). Yu et al. (2012) described the
phenotype of five 2q13 patients alongside 14 additional cases from a
literature review, concluding that 93% of individuals had impaired
development and 63% had facial dysmorphisms. Some of these
patients had a diagnosis of autism spectrum disorder (ASD) or attention
deficit hyperactivity disorder (ADHD), although many were too young
for clinical assessment, or it was unclear whether assessments had
taken place.
Costain et al. (2013) found 2q13 CNVs to be significantly associ-
ated with schizophrenia (p5 .0002) in a community-based schizophre-
nia cohort (N5459), as compared to a large population-based control
sample (N523,838). They identified three 2q13 CNV carriers (one
deletion, two duplications) in cases and four CNV carriers (one deletion,
three duplications) in controls (Costain et al., 2013). However, subse-
quent case-control studies in larger schizophrenia patient cohorts have
failed to find a significant association at the 2q13 locus (Marshall et al.,
2017; Rees et al., 2016). In a follow up study Costain et al. (2014)
undertook detailed phenotyping with two unrelated 2q13 duplication
carriers and their families, identified in the 2013 study. Four family
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members, from one patient pedigree, also carried the duplication and
this co-segregated with a neuropsychiatric phenotype. There was a
variable psychiatric phenotype, with one psychotic disorder, two major
mood and/or anxiety disorders, and one mood and/or anxiety disorder
and obsessive compulsive disorder (OCD). The original patient with
schizophrenia also had OCD. None of these individuals had significant
DD, ASD or facial dysmorphisms, although three of the family members
and one patient had learning difficulties (Costain et al., 2014).
Riley et al. (2015) identified three 2q13 deletion carriers and one
2q13 duplication carrier, and compared the phenotype with previous
published cases. They concluded that congenital heart defects, hypoto-
nia, dysmorphic features, and abnormal head size are common in dele-
tion carriers and DD, dysmorphic features, and abnormal head size are
common in duplication carriers. No ASD or psychiatric phenotype was
described in these patients, likely because they were too young for
clinical assessment (Riley et al., 2015). Finally, Hladilkova et al. (2015)
described two additional 2q13 deletion patients, one of whom had
ASD and ADHD.
A large study of rare CNVs estimated the rate of occurrence of
2q13 deletions and duplications in healthy controls (0.004% deletions,
0.015% duplications), schizophrenia patients (0.015% deletions, 0.02%
duplications), and a mixed developmental disorders (predominantly
DD/ID and ASD) cohort (0.057% deletions, 0.022%, duplications) (Rees
et al., 2016). This suggests that 2q13 CNVs can be observed in healthy
controls, but are more common in schizophrenia cohorts, and even
more common in patients with developmental disorders. The 2q13
CNV is now understood to be a susceptibility locus, which describes a
CNV that can be inherited from a healthy or mildly affected parent, but
is enriched in individuals with various developmental disorders (De
Wolf, Brison, Devriendt, & Peeters, 2013).
A limitation of current 2q13 CNV literature is that few studies
have undertaken comprehensive behavioral and psychiatric phenotyp-
ing, so the full extent of the neuropsychiatric risk associated with these
CNVs remains unclear. We aimed to further delineate the 2q13 CNV
profile by undertaking deep phenotyping comprising: developmental,
medical, dysmorphic, behavioral, and psychiatric features.
2 | MATERIALS AND METHODS
2.1 | Participant recruitment
In order to maximize recruitment of patients with this rare CNV a
multi-faceted approach to recruitment was employed. Unique is a
U.K.-based support group (http://www.rarechromo.org), working inter-
nationally to inform and support anyone affected by a rare chromo-
some or single gene disorder and with professionals involved in their
care. The Unique Information Officer identified and emailed registered
contacts of Unique members with 2q13 CNVs. Information was pro-
vided about the study, and contacts were encouraged to contact the
study team if they wanted to participate. Patients with 2q13 deletions
were also identified via two National Health Service (NHS) Regional
Genetics Centres (RGCs)—the North East and South East Thames
RGCs. Clinicians were approached in the first instance and where
appropriate invitations to participate in the study were sent to the
patient contact via letter.
Additionally, patients with 2q13 CNVs on the DatabasE of
genomiC varIation and Phenotype in Humans using Ensembl Resources
(DECIPHER) database (https://decipher.sanger.ac.uk/) were identified
and further phenotypic information was sought from responsible clini-
cians. One participant was also included from a previous investigation
of CNVs in adults recruited from ID psychiatry services (Wolfe et al.,
2017). Informants or clinicians were asked whether the participant had
taken place in previous research projects, and to the best of our knowl-
edge none of the other patients have been presented in previous stud-
ies. Ethical approval for the study was attained from the North Wales
Research Ethics Committee West, reference 11/WA/0370.
2.2 | Phenotyping and analysis protocol
All participants recruited through Unique and the NHS RGCs (n510),
referred to as the detailed phenotyping group, underwent deep pheno-
typing. Clinical data, including medical and psychiatric history, was col-
lected from a parent in a face-to-face interview. This was conducted by
KW and interviews were undertaken in person for U.K. recruits and via
Skype for overseas recruits. Responsible DECIPHER contacts were
contacted via email to provide further phenotypic data about their
patients and anonymized data was collected via the University College
London (UCL) web-based survey tool Opinio (n515).
All phenotypes were converted to human phenotype ontology
(HPO) terms for presentation in the manuscript (K€ohler et al., 2017).
The level of ID was taken from available medical records or reported
by informants or clinicians and was categorized in accordance with the
HPO criteria: borderline intellectual disability (IQ 70–79), mild intellec-
tual disability (IQ 50–69), moderate intellectual disability (IQ 35–49),
and severe intellectual disability (IQ 20–34).
Clinical psychiatric diagnoses were taken from available medical
records, or from informant or clinician reports. Additional psychiatric
and behavioral phenotyping was undertaken for the detailed phenotyp-
ing group. Psychiatric phenotyping was undertaken using the Mini
Psychiatric Assessment Schedule for Adults with Developmental Dis-
abilities (Mini PAS-ADD) for participants over 18 years of age, and the
Child and Adolescent Psychiatric Assessment Schedule (ChA-PAS) for
those under 18. These assessments provide threshold scores for
psychiatric symptoms that are likely to warrant a diagnosis in conjunc-
tion with a clinical psychiatric assessment (Moss et al., 1998). The Mini
PAS-ADD includes ASD screening, but does not include an ADHD
assessment. The ADHD section of the CHA-PAS requires a second
informant, who is familiar with the individual in other contexts (typically
a teacher). It was not possible to interview a second informant for the
ChA-PAS, so both sections were completed by the primary informant.
Behavioral phenotyping was undertaken using the behavior prob-
lems inventory—short form (BPI-S). The BPI-S provides frequency
scores of self-injurious and aggressive/destructive behaviors (Rojahn
et al., 2012). Behaviors were reported as present if they occurred at a
minimum of a weekly frequency on the BPI-S measure, or were docu-
mented in the medical history. General observations for dysmorphic
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features were also made and photographs taken where consent was
given. Dysmorphic features were independently verified by a second
investigator (NB, Consultant Psychiatrist).
Data analysis and visualization was undertaken using R version
3.4.2 and the ggplot2, Rcmdr, and ontologyX packages (Fox, 2005;
Greene, Richardson, & Turro, 2017; R Core Team., 2017; Wickham,
2009). For the breakdown of CNV carriers for each phenotype, deletion
and duplication will be abbreviated to del and dup. Finally, a literature
search was undertaken on PubMed using the search terms “2q13 dele-
tion” and “2q13 duplication” to identify previously published 2q13 case
reports for combined phenotypic analysis. The supplementary table
detailing the phenotype of patients from previously published studies
has been adapted from the table initially presented by Hladilkova et al.
(permission via personal correspondence) (Hladilkova et al., 2015).
3 | RESULTS
3.1 | Sample description
A total of 25 participants were recruited to the study, 10 from the
Unique and NHS RGCs group and 15 from the Decipher group (64%
male). The participants were predominantly children (92% <18 years of
age, median age 9 years, range 4–42 years). The data set comprises 21
deletion and 4 duplication carriers. The CNVs ranged in size from 1.4
Mb to 2.1 Mb, with a 1.3 Mb region of overlap between all CNVs
(chr2:111449141–112746937, hg19), see Figure 1. One family with an
inherited 2q13 deletion is included in the case series, a father and two
children, as removing the family did not change the results they are
presented together with the rest of the cohort. Detailed phenotypic
data for all cases is presented in Supporting Information Table S1.
3.2 | Inheritance status
For 36% of participants the inheritance status was unknown (8 del,
1 dup). A further 20% (5 del) had de novo CNVs, 28% (5 del, 2 dup)
had a paternally inherited CNV, 8% (1 del, 1 dup) had a maternally
inherited CNV, and finally 8% (2 del) had inherited CNVs but the paren-
tal origin was unknown. Focusing on the 11 individuals with inherited
2q13 CNVs, four (33%, 2 del, 2 dup) had no family history of ID or
mental health problems, four had a family history of ID and/or mental
health problems (36%, 4 del), and three (25%, 2 del, 1 dup) had a family
history of ID and/or mental health problems only on the side of the
family from which the 2q13 CNV was not transmitted.
3.3 | Intellectual and learning difficulties
Overall 76% of participants had DD (15 del, 4 dup). Just over half the
participants had an IQ in the borderline or average range (52%, 10 del,
3 dup), and (32%, 8 del) had mild ID. There were no individuals with
moderate ID and 12% had severe ID (2 del, 1 dup). We also asked
informants or clinicians whether the participants had any other specific
learning difficulties, four participants (16%) had dyslexia, two partici-
pants (8%) had dyscalculia, and two participants (8%) had an auditory
processing disorder (all these were identified in del carriers only).
FIGURE 1 Chromosomal location of the CNV breakpoints for 2q13 CNV carriers (n525). The top of the image shows the location of the
CNV region (highlighted by a red box) on a schematic of chromosome 2. The chromosomal breakpoints for each participant are shown by
the red (representing CNV deletions) and green (representing CNV duplications) boxes. UCSC genes contained in the 2q13 region are
shown. The blue highlighted box displays the 1.3 Mb region of overlap between CNVs. The image was exported from UCSC in
chromosomal build GRCh37/hg19 [Color figure can be viewed at wileyonlinelibrary.com]
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3.4 | Psychiatric disorders and challenging behaviors
In total 64% of participants had a formal psychiatric diagnosis, among
these 44% (9 del, 2 dup) had one diagnosis and 20% (4 del, 1 dup) had
two. The most frequently diagnosed psychiatric disorder was ADHD
(44%, 9 del, 2 dup), followed by ASD (24%, 5 del, 1 dup) and anxiety
disorders (12%, 2 del, 1 dup). Both aggressive and self-injurious behav-
iors were also identified in the participants, eight had aggressive behav-
iors (32%, all del) and eight had self-injurious behaviors (32%, 7 del, 1
dup), for an overview see Figure 2.
Of the detailed phenotyping group (n510), five had no clinical
psychiatric diagnosis. For two of these participants, both aged 6,
ADHD was suspected, but the families were awaiting formal clinical
assessment. Additionally, ASD was suspected for one of these partici-
pants. Taking into account the PAS-ADD and ChA-PAS thresholds,
9/10 individuals reached one or more of the thresholds. The most
frequent thresholds met were anxiety disorder (60%, all del) and manic
episode (60%, 5 del, 1 dup), followed by 20% each for ADHD, depres-
sive disorder and psychosis (all del).
3.5 | Medical and dysmorphology phenotypes
The most commonly observed medical phenotypes were: glue ear
(40%, 9 del, 1 dup), followed by muscular hypotonia (28%, 6 del,
1 dup), sleep disturbances (28%, 6 del, 1 dup), arthralgia (24%, 6 del),
recurrent infections of the middle ear (20%, 4 del, 1 dup), joint
hypermobility (20%, 5 del), and gastroesophageal reflux (16%, 4 del).
The most commonly observed dysmorphology phenotypes were:
macrotia (24%, 6 del), abnormality of the skull (24%, 3 del, 3 dup), mac-
rocephaly (16%, 4 del), upslanted palpebral fissure (16%, 3 del, 1 dup),
hypertelorism (16%, 4 del), strabismus (16%, 2 del, 2 dup), and
depressed nasal bridge (16%, 4 del). See Figures 3 and 4 for an over-
view of the systems affected.
3.6 | Combined phenotypic analysis
A review of the previous literature identified 11 published studies
with phenotypic data for 2q13 deletion carriers (Bisgaard et al.,
2007; Cooper et al., 2011; Costain et al., 2013; Hladilkova et al.,
2015; Riley et al., 2015; Roberts, Hovanes, Dasouki, Manzardo, &
Butler, 2014; Rudd et al., 2009; Russell et al., 2014; Vuillaume et al.,
2014; Yu et al., 2016, 2012) and seven published studies with pheno-
typic data for 2q13 duplication carriers (Cooper et al., 2011; Costain
et al., 2013, 2014; Riley et al., 2015; Roberts et al., 2014; Rudd et al.,
2009; Yu et al., 2012) (some studies include both deletion and
duplication carriers). Comprehensive phenotypic data for controls or
unaffected parents was not available and is not considered in this
analysis. Table 1 presents an overview of all known 2q13 deletion
and duplication patient cases to date, including the participants from
this study, and the phenotypes observed. Detailed phenotypic data
FIGURE 2 Clinically diagnosed psychiatric disorders and
behavioral phenotypes in 2q13 deletion (n521) and duplication
(n54) carriers. Y axis: percentage of participants with the
diagnosis or behavior; X axis: ADHD—attention deficit
hyperactivity disorder, Aggressive—aggressive behaviors, Anxiety—
anxiety disorder, Autism—autism spectrum disorder, ODD—
oppositional defiant disorder, Self-injurious—self-injurious behaviors
[Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 3 Human phenotype ontology tree plot with ancestral ontologies for the medical phenotypes occurring in more than three
participants [Color figure can be viewed at wileyonlinelibrary.com]
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for the patients described in these studies is available in Supporting
Information Table S2.
4 | DISCUSSION
CNVs at the 2q13 locus are rare in the population, can be observed in
healthy controls and transmitted from unaffected parents. Despite this,
multiple studies have now shown that CNVs at 2q13 are risk factors
for DD and dysmorphisms. This study represents the largest ever case
series of 2q13 patients, comprising detailed phenotypic data for 25
new cases and combined analysis in 77 individuals, refining our under-
standing of the phenotypic associations of CNVs at the 2q13 locus.
DD was identified in 76% of participants in this study. Combined
with data from existing studies 79% of deletion carriers and 70% of
duplication carriers have DD/ID. We have further delineated this phe-
notype by investigating the level of ID, finding that the intellectual
impairment is generally mild and 52% of participants have IQ in the
borderline or average range. Only 12% of participants had severe ID,
and data available for two of these participants revealed that both
were referred for further exome sequencing investigations, due to the
2q13 CNV not being thought to fully explain their phenotype.
Combined analysis reveals that 80% of 2q13 deletion carriers and
90% of 2q13 duplication carriers have dysmorphic features. Deep
phenotyping in the new cases showed that macrotia, abnormalities of
the skull, macrocephaly, upslanted palpebral fissures, hypertelorism,
strabismus, and depressed nasal bridge were common in deletion
carriers. In duplication carriers, abnormalities of the skull and strabis-
mus were observed. No other features achieved more than a single
occurrence, however there were only four individuals who had 2q13
duplications. Combined analysis identified 29% of deletion carriers and
14% of duplication carriers as having macrocephaly and 23% of dele-
tion carriers and 29% of duplication carriers as having microcephaly.
Previous 2q13 CNV literature has described congenital heart
defects, hypotonia and seizures as associated medical phenotypes.
Combined analysis found that 31% of deletion carriers had heart
defects, and this phenotype was not observed in duplication carriers.
Combined analysis identified 44% of deletion carriers and 43% of
duplication carriers as having hypotonia, supporting previous results on
FIGURE 4 Human phenotype ontology tree plot with ancestral ontologies for the dysmorphology phenotypes occurring in more than three
participants [Color figure can be viewed at wileyonlinelibrary.com]
TABLE 1 Summary of phenotypic observations in 2q13 deletion
and duplication carriers (comprising the results of this study and
available phenotypes from previously published studies)
2q13 deletions 2q13 duplications
DD/ID 31/39 (79%) 14/20 (70%)
ASDs 9/27 (33%) 2/12 (17%)
ADHD 12/25 (48%) 3/5 (60%)
Dysmorphic features 33/41 (80%) 9/10 (90%)
Heart defect 11/35 (31%) 0/5 (0%)
Hypotonia 15/34 (44%) 3/7 (43%)
Seizures 8/31 (26%) 0/10 (0%)
Macrocephaly 10/35 (29%) 1/7 (14%)
Microcephaly 8/35 (23%) 2/7 (29%)
For each phenotype the number of patients with the diagnosis is dis-
played alongside the number of patients for which the phenotype was
assessed. Thus, the denominator differs due to the varying availability of
phenotypic information in published case studies. Percentages are pro-
vided for each individual phenotype. ADHD5 attention deficit hyperac-
tivity disorder; ASDs5 autism spectrum disorders; DD5developmental
delay; ID5 intellectual disabilities
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the association of the 2q13 deletion with this feature and extending
this to also affect duplication carriers. Seizures were only observed in
deletion carriers at a frequency of 26%. Deep phenotyping in this study
also associated novel medical phenotypes with 2q13 CNVs, including:
glue ear, sleep disturbances and recurrent infections of the middle ear,
both in deletion and duplication carriers, and arthralgia, joint hypermo-
bility, and gastroesophageal reflux in deletion carriers only.
A limitation of published 2q13 case reports is that many are in
young children, who are below the typical assessment age for various
psychiatric disorders. Also, it is unclear in some studies whether com-
prehensive behavioral and mental health assessments have taken place.
The new cases presented in this study had a median age of 9 years,
and 64% already had a clinical psychiatric diagnosis. Some of the
remaining participants either had suspected psychiatric disorders,
which had yet to be formally tested, or met PAS-ADD thresholds, indi-
cating that this figure could be even higher. To our knowledge, chal-
lenging behaviors have never previously been assessed in 2q13 CNV
carriers and we found both aggressive and self-injurious behaviors to
be present in deletion carriers and self-injurious behaviors in one
duplication carrier.
Despite the aforementioned limitations, previous case reports of
individuals with 2q13 CNVs have reported both ASD and ADHD
diagnoses. Combining analysis identified 48% of deletion carriers and
60% of duplication carriers as having an ADHD diagnosis, and 33% of
deletion carriers and 17% of duplication carriers as having an ASD diag-
nosis. Both 2q13 deletions and duplications have also been identified
in schizophrenia patients. We did not identify any participants with
schizophrenia, although only three individuals were over the age of 16,
so the typical age of onset was not reached in most individuals. Our
study identifies a strikingly high incidence of ADHD in 2q13 CNV car-
riers. A literature review of genes in the 2q13 region was undertaken
and no prior association of genes in this region with risk for ADHD was
identified, although postulations have been made about the involve-
ment of genes in the region in other neuropsychiatric phenotypes.
We identified a 1.3 Mb common region of overlap in the new
cases described in this study, encompassing four genes: ACOXL,
BCL2L11, ANAPC1, and MERTK. It has been suggested that disruption
of the ACOXL and BCL2L11 genes may contribute to neurodevelop-
mental and ASD phenotypes (Yu et al., 2012). The ACOXL gene enco-
des a protein responsible for fatty acid oxidization, and alterations in
fatty acid metabolism have been proposed to play a role in the patho-
genesis of ASD (Wiest, German, Harvey, Watkins, & Hertz-Picciotto,
2009). BCL2L11 encodes a neuronal apoptosis regulator and previous
research has found decreased expression of this gene in the frontal
cortex and cerebellum of autistic subjects. It has been hypothesized
that an increase in apoptosis in these regions may contribute to the
pathogenicity of ASD (Sheikh et al., 2010). ANAPC1, a neurodevelop-
mental facilitator, and MERTK, a TAM receptor and multiple sclerosis
risk gene, have also been proposed as candidate genes for the psycho-
sis phenotype of 2q13 CNV carriers (Costain et al., 2013). All but one
participant had CNVs which extend distally to include FBLN7 and
TMEM87B. Russell et al. (2014) undertook a functional analysis of can-
didate genes in the 2q13 region using zebrafish morpholino
knockdowns. They found that depletion of FBLN7 and TMEM87B
orthologues resulted in cardiac hypoplasia and FBLN7 depletion was
also associated with craniofacial abnormalities (Russell et al., 2014).
One theory as to why some CNVs show incomplete penetrance is
that a second genetic hit is required to unmask the predisposition to a
neuropsychiatric phenotype (Girirajan et al., 2010). None of the partici-
pants in this study had another CNV that had been classified as patho-
genic. However, as sequencing data was not available for analysis, it
cannot be ruled out that another genetic variant was contributing the
phenotype. Yu et al. (2016) recently identified a paternally inherited
variant in the TMEM87B gene, one of the genes in the 2q13 region
associated with the cardiac phenotype (Russell et al., 2014), in a patient
with a severe cardiac phenotype who also had a maternal 2q13 dele-
tion. It is thought that the unmasking of this homozygous variant by
the maternal deletion acted as a second genetic hit, resulting in the
severe phenotype (Yu et al., 2016). The inheritance pattern of 2q13
CNVs was mixed, as was the family history of ID and mental health
problems. It is of interest that 25% of the new cases who had inherited
CNVs had a family history of ID and mental health problems on the
other side of the family from which the variant was transmitted. This
could provide support to the second-hit hypothesis, but further genetic
investigations would be required.
One of the benefits of receiving a genetic diagnosis for patients
and their families is the ability to access diagnosis specific information,
which could be used to facilitate early intervention screening for
associated medical and psychiatric phenotypes. Disorder guides,
written for both professionals and families, are available for 2q13
CNVs from the patient support group unique (http://www.rarechromo.
co.uk/html/DisorderGuides.asp). The findings from combined analyses
in this study could also guide clinical management of individuals with
newly diagnosed 2q13 CNVs. However, it must be acknowledged that
while we find some phenotypes to occur more frequently, 2q13 CNV
carriers still display variable phenotypic outcomes—posing challenges
for genetic counseling of patients and their families. Many studies of
rare CNVs have been undertaken in pediatric cohorts, and comprehen-
sive psychiatric and behavioral phenotyping has not been carried out.
The degree to which neuropsychiatric phenotypes are common in rare
CNV carriers has, therefore, yet to be established. More research is
required in this area and ongoing mental health assessments in 2q13
carriers will be required to elucidate associations with psychiatric
disorders across the life course. Additionally, further studies of the
unaffected parents and healthy controls with 2q13 CNVs will be
important to elucidate potential protective factors.
The limitations of this study are that observations are being made
in participants who have presented to clinical services. This may create
an ascertainment bias, whereby the most severe cases are described.
However, the accumulation of cases from a wide range of sources
attempted to ensure as representative a sample as possible. The
assessments of dysmorphology were not conducted by a clinical
dysmorphology expert, although we utilized a second rater to improve
the reliability of the observations. The PAS-ADD and ChA-PAS
schedules were completed by a researcher, and clinical verification by a
trained psychiatrist did not take place. Some of the participants were
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as young as four, meaning some of the later-onset phenotypes could
not be accurately measured at this age. However, if anything this
would have led to an under estimation of the phenotype frequencies.
5 | CONCLUSIONS
In the largest study of 2q13 CNVs to date, we present detailed pheno-
typic data for 25 new 2q13 deletion and duplication carriers. Combin-
ing this with previous literature yields a total of 54 deletion and 23
duplication carriers, enabling a refined understanding of the phenotypic
associations of CNVs at the 2q13 locus. Combined analysis predomi-
nantly supports existing literature on an increased rate of developmen-
tal, medical, and dysmorphic phenotypes. Psychiatric investigations
reveal that the majority of deletion and duplication carriers have been
clinically diagnosed with a psychiatric disorder, with a particularly high
incidence of ADHD. This could have important implications for psychi-
atric screening upon clinical diagnosis of 2q13 CNVs, and further inves-
tigation of this region may have some relevance to understanding the
neurobiology of ADHD.
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